Randomized controlled and prospective clinical study of probiotics in the treatment of cerebral amyloid angiopathy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100047104

Enrollment

Unknown

Registered

2021-06-08

Start date

2021-06-08

Completion date

Unknown

Last updated

2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral amyloid angiopathy

Interventions

treatment group:pobiotics

control group:placebo

Eligibility

Sex/Gender

All

Age

55 Years to No maximum

Inclusion criteria

Inclusion criteria: CAA Diagnostic Standard Reference 2010 Revised Boston CAA Diagnostics This study of CAA patients included and excluded as follows: 1.Aged >= 55 years; 2.Clinical data and MRI or CT display: Confirmant to cerebral leaf, cortical or cortex - skinned or micro-blood (including cerebellum), or single cerebella, cortical or cortex, cortex, bleeding or micro-blood, or Cooking or diffuse brain surface iron calories; 3.Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1.Excluding the bleeding caused by other causes such as trauma, tumors; 2.Allergic to drugs.

Design outcomes

Primary

Measure	Time frame
Montreal Cognitive Assessment Scale (MoCa);	—

Secondary

Measure	Time frame
gait scale;high density electroencephalogram;brain magnetic resonance imaging;intestinal flora;neurotransmitters;immune markers in blood;anxiety depression score;sleep assessment;	—

Countries

China

Contacts

Public ContactLu Zhengqi

Third Affiliated Hospital of Sun Yat-Sen University

lzq1828@aliyun.com+86 13570102668

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026